|
1
|
Prieto PA, Reuben A, Cooper ZA and Wargo
JA: Targeted Therapies Combined With Immune Checkpoint Therapy.
Cancer J. 22:138–146. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhang Z, Guo Y and Feng SS:
Nanoimmunotherapy: Application of nanotechnology for sustained and
targeted delivery of antigens to dendritic cells. Nanomedicine
(Lond). 7:1–4. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rosenberg SA, Yang JC and Restifo NP:
Cancer immunotherapy: Moving beyond current vaccines. Nat Med.
10:909–915. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Melero I, Grimaldi AM, Perez-Gracia JL and
Ascierto PA: Clinical development of immunostimulatory monoclonal
antibodies and opportunities for combination. Clin Cancer Res.
19:997–1008. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mellman I, Coukos G and Dranoff G: Cancer
immunotherapy comes of age. Nature. 480:480–489. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Blackburn SD, Shin H, Haining WN, Zou T,
Workman CJ, Polley A, Betts MR, Freeman GJ, Vignali DA and Wherry
EJ: Coregulation of CD8+ T cell exhaustion by multiple
inhibitory receptors during chronic viral infection. Nat Immunol.
10:29–37. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yu P, Steel JC, Zhang M, Morris JC and
Waldmann TA: Simultaneous blockade of multiple immune system
inhibitory checkpoints enhances antitumor activity mediated by
interleukin-15 in a murine metastatic colon carcinoma model. Clin
Cancer Res. 16:6019–6028. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ramos-Suzarte M, Lorenzo-Luaces P, Lazo
NG, et al: Treatment of malignant, non-resectable, epithelial
origin esophageal tumours with the humanized anti-epidermal growth
factor antibody nimotuzumab combined with radiation therapy and
chemotherapy. Cancer Biol Ther. 13:600–605. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dong JM, Zhao SG, Huang GY and Liu Q:
NADPH oxidase-mediated generation of reactive oxygen species is
critically required for survival of undifferentiated human
promyelocytic leukemia cell line HL-60. Free Radic Res. 38:629–637.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Oleson JR: Eugene Robertson Special
Lecture. Hyperthermia from the clinic to the laboratory: A
hypothesis. Int J Hyperthermia. 11:315–322. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vujaskovic Z and Song CW: Physiological
mechanisms underlying heat-induced radiosensitization. Int J
Hyperthermia. 20:163–174. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sanson C, Diou O, Thévenot J, Ibarboure E,
Soum A, Brûlet A, Miraux S, Thiaudière E, Tan S, Brisson A, et al:
Doxorubicin loaded magnetic polymersomes: Theranostic nanocarriers
for MR imaging and magneto-chemotherapy. ACS Nano. 5:1122–1140.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kouloulias V, Plataniotis G, Kouvaris J,
Dardoufas C, Gennatas C, Uzunoglu N, Papavasiliou C and Vlahos L:
Chemoradiotherapy combined with intracavitary hyperthermia for anal
cancer: Feasibility and long-term results from a phase II
randomized trial. Am J Clin Oncol. 28:91–99. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Westermann AM, Jones EL, Schem BC, et al:
First results of triple-modality treatment combining radiotherapy,
chemotherapy, and hyperthermia for the treatment of patients with
stage IIB, III, and IVA cervical carcinoma. Cancer. 104:763–770.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Westermann A, Mella O, Van Der Zee J,
Jones ELE, Van Der Steen-Banasik E, Koper P, Uitterhoeve AL, De Wit
R, Van Der Velden J, Burger C, et al: Long-term survival data of
triple modality treatment of stage IIB-III-IVA cervical cancer with
the combination of radiotherapy, chemotherapy and hyperthermia - an
update. Int J Hyperthermia. 28:549–553. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Vujaskovic Z, Kim DW, Jones E, Lan L,
McCall L, Dewhirst MW, Craciunescu O, Stauffer P, Liotcheva V,
Betof A and Blackwell K: A phase I/II study of neoadjuvant
liposomal doxorubicin, paclitaxel, and hyperthermia in locally
advanced breast cancer. Int J Hyperthermia. 26:514–521. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tschoep-Lechner KE, Milani V, Berger F,
Dieterle N, Abdel-Rahman S, Salat C and Issels RD: Gemcitabine and
cisplatin combined with regional hyperthermia as second-line
treatment in patients with gemcitabine-refractory advanced
pancreatic cancer. Int J Hyperthermia. 29:8–16. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wessalowski R, Kruck H, Pape H, Kahn T,
Willers R and Göbel U: Hyperthermia for the treatment of patients
with malignant germ cell tumors: A phase I/II study in ten children
and adolescents with recurrent or refractory tumors. Cancer.
82:793–800. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Issels RD: Hyperthermia adds to
chemotherapy. Eur J Cancer. 44:2546–2554. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lindquist S and Craig EA: The heat-shock
proteins. Annu Rev Genet. 22:631–677. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kumar CS and Mohammad F: Magnetic
nanomaterials for hyperthermia-based therapy and controlled drug
delivery. Adv Drug Deliv Rev. 63:789–808. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Boisselier E and Astruc D: Gold
nanoparticles in nanomedicine: Preparations, imaging, diagnostics,
therapies and toxicity. Chem Soc Rev. 38:1759–1782. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Day ES, Morton JG and West JL:
Nanoparticles for thermal cancer therapy. J Biomech Eng.
131:0740012009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kerbel R and Folkman J: Clinical
translation of angiogenesis inhibitors. Nat Rev Cancer. 2:727–739.
2002. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Folkman J: Angiogenesis: An organizing
principle for drug discovery? Nat Rev Drug Discov. 6:273–286. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Folkman J: Angiogenesis. Annu Rev Med.
57:1–18. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kamrava M, Bernstein MB, Camphausen K and
Hodge JW: Combining radiation, immunotherapy, and antiangiogenesis
agents in the management of cancer: The Three Musketeers or just
another quixotic combination? Mol Biosyst. 5:1262–1270. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kandalaft LE, Powell DJ Jr, Chiang CL,
Tanyi J, Kim S, Bosch M, Montone K, Mick R, Levine BL, Torigian DA,
et al: Autologous lysate-pulsed dendritic cell vaccination followed
by adoptive transfer of vaccine-primed ex vivo co-stimulated T
cells in recurrent ovarian cancer. OncoImmunology. 2:e226642013.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fabi A, Russillo M, Ferretti G, Metro G,
Nisticò C, Papaldo P, De Vita F, D'Auria G, Vidiri A, Giannarelli D
and Cognetti F: Maintenance bevacizumab beyond first-line
paclitaxel plus bevacizumab in patients with Her2-negative hormone
receptor-positive metastatic breast cancer: Efficacy in combination
with hormonal therapy. BMC Cancer. 12:4822012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dolmans DEJGJ, Fukumura D and Jain RK:
Photodynamic therapy for cancer. Nat Rev Cancer. 3:380–387. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Baldea I and Filip AG: Photodynamic
therapy in melanoma - an update. J Physiol Pharmacol. 63:109–118.
2012.PubMed/NCBI
|
|
32
|
Zuluaga MF and Lange N: Combination of
photodynamic therapy with anti-cancer agents. Curr Med Chem.
15:1655–1673. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Brown SB, Brown EA and Walker I: The
present and future role of photodynamic therapy in cancer
treatment. Lancet Oncol. 5:497–508. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Agostinis P, Berg K, Cengel KA, Foster TH,
Girotti AW, Gollnick SO, Hahn SM, Hamblin MR, Juzeniene A, Kessel
D, et al: Photodynamic therapy of cancer: An update. CA Cancer J
Clin. 61:250–281. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Friedberg JS, Mick R, Stevenson J, Metz J,
Zhu T, Buyske J, Sterman DH, Pass HI, Glatstein E and Hahn SM: A
phase I study of Foscan-mediated photodynamic therapy and surgery
in patients with mesothelioma. Ann Thorac Surg. 75:952–959. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Thomas CE, Ehrhardt A and Kay MA: Progress
and problems with the use of viral vectors for gene therapy. Nat
Rev Genet. 4:346–358. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
37
|
McCormick F: Cancer gene therapy: Fringe
or cutting edge? Nat Rev Cancer. 1:130–141. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
DeVincenzo JP: The promise, pitfalls and
progress of RNA-interference-based antiviral therapy for
respiratory viruses. Antivir Ther 17 (1 Pt B). 213–225. 2012.
View Article : Google Scholar
|
|
39
|
Izquierdo M: Short interfering RNAs as a
tool for cancer gene therapy. Cancer Gene Ther. 12:217–227. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ginn SL, Alexander IE, Edelstein ML, Abedi
MR and Wixon J: Gene therapy clinical trials worldwide to 2012 - an
update. J Gene Med. 15:65–77. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
41
|
Davidson BL and McCray PB Jr: Current
prospects for RNA interference-based therapies. Nat Rev Genet.
12:329–340. 2011. View
Article : Google Scholar : PubMed/NCBI
|
